ArticleJournal of lipid research2015
Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease.
Article in Journal of lipid research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 78 citations in OpenAlex.
- Free Fatty Acids Carried by Lipoproteins: Revisiting the Overlooked Cargo.Acta physiologica (Oxford, England) · 2026Review
- Trans fatty acids alter renal health in TGFβ3 mice with fibrosis revealed by metabolomics and lipidomics.iScience · 2026Article
- Declining eGFR and Uremia Are Associated with Remnant Cholesterol Accumulation and Reduced HDL-C in Non-Dialysis Chronic Kidney Disease.Journal of clinical medicine · 2026Article
- Impact of Sex, Age, Body Composition and Kidney Function on the Relationship Between Self-Reported Alcohol Consumption and Phosphatidylethanol-Data From the HUNT Study.Basic & clinical pharmacology & toxicology · 2025Article
- Lipidomics Unveils Critical Lipid Pathway Shifts in Alport Syndrome.Kidney international reports · 2025Article
- Proteomic and lipidomic analysis of low-density lipoprotein identifies potential biomarkers of early estrogen receptor-positive breast cancer.Cancer & metabolism · 2025Article
- The prognostic value of remnant cholesterol to adverse renal outcomes in patients with type 2 diabetes.Diabetology & metabolic syndrome · 2025Article
- Review
- The association between monocyte to high-density lipoprotein cholesterol ratio and chronic kidney disease in a Chinese adult population: a cross-sectional study.Renal failure · 2024Article
- Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients.International journal of molecular sciences · 2024Review
- Sex-Associated Metabolites and Incident Stroke, Incident Coronary Heart Disease, Hypertension, and Chronic Kidney Disease in the REGARDS Cohort.Journal of the American Heart Association · 2024Article
- Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy.Current atherosclerosis reports · 2024Review
- Circulating Lipoprotein Sphingolipids in Chronic Kidney Disease with and without Diabetes.Biomedicines · 2024Article
- Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease.Frontiers in pharmacology · 2023Article
- Lipidomic profiling in the Strong Heart Study identified American Indians at risk of chronic kidney disease.Kidney international · 2022Article
- Lipidic profiles of patients starting peritoneal dialysis suggest an increased cardiovascular risk beyond classical dyslipidemia biomarkers.Scientific reports · 2022Observational
- The Roles of Fatty Acids and Apolipoproteins in the Kidneys.Metabolites · 2022Review
- Relationship between lipoproteins, thrombosis, and atrial fibrillation.Cardiovascular research · 2022Review
- Deletion of Alox15 improves kidney dysfunction and inhibits fibrosis by increased PGDClinical and experimental nephrology · 2021Article
- Mass Spectrometry-Based Lipidomics Reveals Differential Changes in the Accumulated Lipid Classes in Chronic Kidney Disease.Metabolites · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
This study compared the molecular lipidomic profile of LDL in patients with nondiabetic advanced renal disease and no evidence of CVD to that of age-matched controls, with the hypothesis that it would reveal proatherogenic lipid alterations. LDL was isolated from 10 normocholesterolemic patients with stage 4/5 renal disease and 10 controls, and lipids were analyzed by accurate mass LC/MS. Top-down lipidomics analysis and manual examination of the data identified 352 lipid species, and automated comparative analysis demonstrated alterations in lipid profile in disease. The total lipid and cholesterol content was unchanged, but levels of triacylglycerides and N-acyltaurines were significantly increased, while phosphatidylcholines, plasmenyl ethanolamines, sulfatides, ceramides, and cholesterol sulfate were significantly decreased in chronic kidney disease (CKD) patients. Chemometric analysis of individual lipid species showed very good discrimination of control and disease sample despite the small cohorts and identified individual unsaturated phospholipids and triglycerides mainly responsible for the discrimination. These findings illustrate the point that although the clinical biochemistry parameters may not appear abnormal, there may be important underlying lipidomic changes that contribute to disease pathology. The lipidomic profile of CKD LDL offers potential for new biomarkers and novel insights into lipid metabolism and cardiovascular risk in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.